Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study

BACKGROUND AND AIMS: Ustekinumab is approved for the treatment of Crohn’s disease [CD]. Systematically registered prospective real-world data are scarce. We therefore aimed to study the effectiveness, safety and usage of ustekinumab for CD in everyday practice. METHODS: We prospectively enrolled CD...

Descripción completa

Detalles Bibliográficos
Autores principales: Biemans, Vince B C, van der Meulen - de Jong, Andrea E, van der Woude, Christine J, Löwenberg, Mark, Dijkstra, Gerard, Oldenburg, Bas, de Boer, Nanne K H, van der Marel, Sander, Bodelier, Alexander G L, Jansen, Jeroen M, Haans, Jeoffrey J L, Theeuwen, Rosaline, de Jong, Dirk, Pierik, Marie J, Hoentjen, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142409/
https://www.ncbi.nlm.nih.gov/pubmed/31219157
http://dx.doi.org/10.1093/ecco-jcc/jjz119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142409/
https://www.ncbi.nlm.nih.gov/pubmed/31219157
http://dx.doi.org/10.1093/ecco-jcc/jjz119

Ejemplares similares